Literature DB >> 30728091

School-age social behavior and pragmatic language ability in children with prenatal serotonin reuptake inhibitor exposure.

Erica L Smearman1,2, Cassandra L Hendrix1, Dominika A Winiarski3, Katrina C Johnson1, Alicia K Smith4,5, Opal Y Ousley4, Zachary N Stowe6, D Jeffrey Newport7, Patricia A Brennan1.   

Abstract

Studies examining associations between fetal serotonin reuptake inhibitor (SRI) exposure and child autism spectrum disorder (ASD) diagnoses or delayed language remain mixed and rarely prospectively follow children or employ gold-standard assessments. We prospectively followed a cohort of mother-child dyads from pregnancy through early elementary school (N = 178), and obtained maternal and alternate-caregiver ratings of behaviors related to ASD (N = 137), as well as direct, gold-standard assessments of child ASD symptoms and pragmatic language among dyads who experienced prenatal depression and either took SRIs or were medication free during pregnancy (N = 44). Prenatal SRI exposure was related to maternal ratings of ASD-related behaviors (β = 0.24 95% confidence interval; CI [0.07, 0.48]), and, among boys, alternative caregiver ratings (males-only β = 0.28 95% CI [0.02, 0.55], females-only β = -0.21 95% CI [-0.63, 0.08]). However, results of our direct assessments suggest an association between SRI exposure and reduced pragmatic language scores (β = -0.27, 95% CI [-0.53, -0.01], but not ASD (Autism Diagnostic Observation Schedule β = 0.14 95% CI [-0.15, 0.41]; Social Responsiveness Scale β = 0.08 95% CI [-0.25, 0.40]). These discrepancies point to issues regarding how ASD is assessed, and the possibility that SRIs may be more strongly associated with language or other broader behaviors that coincide with ASD. Larger prospective studies that incorporate thorough, gold-standard assessments of ASD, language, and other ASD-related behaviors are needed.

Entities:  

Keywords:  Autism Spectrum Disorder; language; neurodevelopment; prenatal exposure; serotonin

Mesh:

Substances:

Year:  2020        PMID: 30728091      PMCID: PMC6685774          DOI: 10.1017/S0954579418001372

Source DB:  PubMed          Journal:  Dev Psychopathol        ISSN: 0954-5794


  58 in total

Review 1.  Serotonin and brain development: role in human developmental diseases.

Authors:  P M Whitaker-Azmitia
Journal:  Brain Res Bull       Date:  2001-11-15       Impact factor: 4.077

2.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

3.  Psychiatric disorders in parents of children with autism: a meta-analysis.

Authors:  Nurit Yirmiya; Michal Shaked
Journal:  J Child Psychol Psychiatry       Date:  2005-01       Impact factor: 8.982

4.  Maternal depression and cortisol in pregnancy predict offspring emotional reactivity in the preschool period.

Authors:  Danielle A Swales; Dominika A Winiarski; Alicia K Smith; Zachary N Stowe; D Jeffrey Newport; Patricia A Brennan
Journal:  Dev Psychobiol       Date:  2018-05-25       Impact factor: 3.038

Review 5.  Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?

Authors:  Salvatore Gentile
Journal:  J Affect Disord       Date:  2015-05-06       Impact factor: 4.839

6.  Chronicity, severity, and timing of maternal depressive symptoms: relationships with child outcomes at age 5.

Authors:  P A Brennan; C Hammen; M J Andersen; W Bor; J M Najman; G M Williams
Journal:  Dev Psychol       Date:  2000-11

7.  Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism.

Authors:  George M Anderson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-12       Impact factor: 8.829

8.  Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children.

Authors:  Takoua Boukhris; Odile Sheehy; Laurent Mottron; Anick Bérard
Journal:  JAMA Pediatr       Date:  2016-02       Impact factor: 16.193

9.  Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.

Authors:  Alan S Brown; David Gyllenberg; Heli Malm; Ian W McKeague; Susanna Hinkka-Yli-Salomäki; Miia Artama; Mika Gissler; Keely Cheslack-Postava; Myrna M Weissman; Jay A Gingrich; Andre Sourander
Journal:  JAMA Psychiatry       Date:  2016-11-01       Impact factor: 21.596

10.  Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort.

Authors:  Anick Bérard; Jin-Ping Zhao; Odile Sheehy
Journal:  BMJ Open       Date:  2017-01-12       Impact factor: 2.692

View more
  4 in total

1.  Prenatal antidepressant exposures and gastrointestinal complaints in childhood: A gut-brain axis connection?

Authors:  Amy L Salisbury; George D Papandonatos; Laura R Stroud; Alicia K Smith; Patricia A Brennan
Journal:  Dev Psychobiol       Date:  2020-03-13       Impact factor: 3.038

2.  Maternal prenatal depression and epigenetic age deceleration: testing potentially confounding effects of prenatal stress and SSRI use.

Authors:  Brooke G McKenna; Cassandra L Hendrix; Patricia A Brennan; Alicia K Smith; Zachary N Stowe; D Jeffrey Newport; Anna K Knight
Journal:  Epigenetics       Date:  2020-07-24       Impact factor: 4.528

3.  Perinatal exposure to fluoxetine and maternal adversity affect myelin-related gene expression and epigenetic regulation in the corticolimbic circuit of juvenile rats.

Authors:  Anouschka S Ramsteijn; Rikst Nynke Verkaik-Schakel; Danielle J Houwing; Torsten Plösch; Jocelien D A Olivier
Journal:  Neuropsychopharmacology       Date:  2022-01-31       Impact factor: 8.294

4.  An inventory of European data sources to support pharmacoepidemiologic research on neurodevelopmental outcomes in children following medication exposure in pregnancy: A contribution from the ConcePTION project.

Authors:  Joanne Given; Rebecca L Bromley; Florence Coste; Sandra Lopez-Leon; Maria Loane
Journal:  PLoS One       Date:  2022-10-14       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.